Description: Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology. Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Home Page: viraxbiolabs.com
VRAX Technical Analysis
30 Broadwick Street
London,
W1F 8LX
United Kingdom
Phone:
44 20 7788 7414
Officers
| Name | Title |
|---|---|
| Mr. James Foster | Chairman & CEO |
| Mr. Jason D. Davis | Chief Financial Officer |
| Mr. Cameron Lee Shaw | COO & Director |
| Mr. Mark James Ternouth | Chief Technical Officer |
| Dr. Tomasz Evan George | Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 712.5641 |
| IPO Date: | 2022-07-21 |
| Fiscal Year End: | March |
| Full Time Employees: | 5 |